BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nøjgaard C, Høst NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA, Johansen JS. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 2008;19:257-63. [PMID: 18480670 DOI: 10.1097/MCA.0b013e3282f40dd5] [Cited by in Crossref: 72] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61. [PMID: 19930630 DOI: 10.1186/1475-2840-8-61] [Cited by in Crossref: 115] [Cited by in F6Publishing: 115] [Article Influence: 8.8] [Reference Citation Analysis]
2 Thomsen SB, Rathcke CN, Jørgensen NB, Madsbad S, Vestergaard H. Effects of Roux-en-Y gastric bypass on fasting and postprandial levels of the inflammatory markers YKL-40 and MCP-1 in patients with type 2 diabetes and glucose tolerant subjects. J Obes 2013;2013:361781. [PMID: 24303210 DOI: 10.1155/2013/361781] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
3 Song CL, Bin-Li, Diao HY, Wang JH, Shi YF, Lu Y, Wang G, Guo ZY, Li YX, Liu JG, Wang JP, Zhang JC, Zhao Z, Liu YH, Li Y, Cai D, Li Q. Diagnostic Value of Serum YKL-40 Level for Coronary Artery Disease: A Meta-Analysis. J Clin Lab Anal 2016;30:23-31. [PMID: 27152377 DOI: 10.1002/jcla.21804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Henningsen KM, Nilsson B, Johansen JS, Chen X, Pehrson S, Svendsen JH. Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation. Inflamm Res 2010;59:463-9. [PMID: 20012147 DOI: 10.1007/s00011-009-0146-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
5 Akboğa MK, Yalçın R, Şahinarslan A, Yılmaz Demirtaş C, Paşaoğlu H, Abacı A. Increased serum YKL-40 level is associated with the presence and severity of metabolic syndrome. Anatol J Cardiol 2016;16:953-8. [PMID: 27443476 DOI: 10.14744/AnatolJCardiol.2016.6933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
6 Røndbjerg AK, Omerovic E, Vestergaard H. YKL-40 levels are independently associated with albuminuria in type 2 diabetes. Cardiovasc Diabetol 2011;10:54. [PMID: 21696606 DOI: 10.1186/1475-2840-10-54] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
7 Wang D, Lu JG, Wang Q, Du XL, Dong R, Wang P, Zhao L, Jiang X, Yuan LJ. Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension. Braz J Med Biol Res 2012;45:264-72. [PMID: 22267006 DOI: 10.1590/s0100-879x2012007500010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
8 Rathcke CN, Kjøller E, Fogh-Andersen N, Zerahn B, Vestergaard H. NT-proBNP and circulating inflammation markers in prediction of a normal myocardial scintigraphy in patients with symptoms of coronary artery disease. PLoS One 2010;5:e14196. [PMID: 21152016 DOI: 10.1371/journal.pone.0014196] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
9 Li K, Chen Z, Qin Y, Wei YX. Plasm YKL-40 Levels Are Associated with Hypertension in Patients with Obstructive Sleep Apnea. Biomed Res Int 2019;2019:5193597. [PMID: 31001555 DOI: 10.1155/2019/5193597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tan H, Yao H, Lie Z, Chen G, Lin S, Zhang Y. MicroRNA‑30a‑5p promotes proliferation and inhibits apoptosis of human pulmonary artery endothelial cells under hypoxia by targeting YKL‑40. Mol Med Rep 2019;20:236-44. [PMID: 31115541 DOI: 10.3892/mmr.2019.10251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
11 Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E. Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol 2009; 15(42): 5249-5259 [PMID: 19908331 DOI: 10.3748/wjg.15.5249] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
12 Xue Q, Chen L, Yu J, Sun K, Ye L, Zheng J. Downregulation of Interleukin-13 Receptor α2 Inhibits Angiogenic Formation Mediated by Chitinase 3-Like 1 in Late Atherosclerotic Lesions of apoE-/- Mice. Front Physiol 2021;12:690109. [PMID: 34349665 DOI: 10.3389/fphys.2021.690109] [Reference Citation Analysis]
13 Sun W, Xue Q, Zhao Y, Zheng J. The effects of YKL-40 on angiogenic potential of HUVECs are partly mediated by syndecan-4. Int J Med Sci 2021;18:3759-67. [PMID: 34790051 DOI: 10.7150/ijms.55406] [Reference Citation Analysis]
14 Chen L, Zheng J, Xue Q, Zhao Y. YKL-40 promotes the progress of atherosclerosis independent of lipid metabolism in apolipoprotein E-/- mice fed a high-fat diet. Heart Vessels 2019;34:1874-81. [PMID: 31114961 DOI: 10.1007/s00380-019-01434-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yang L, Dong H, Lu H, Liao Y, Zhang H, Xu L, Tan Y, Cao S, Tan J, Fu S. Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine (Baltimore) 2019;98:e14920. [PMID: 30896649 DOI: 10.1097/MD.0000000000014920] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hector A, Kormann MS, Mack I, Latzin P, Casaulta C, Kieninger E, Zhou Z, Yildirim AÖ, Bohla A, Rieber N, Kappler M, Koller B, Eber E, Eickmeier O, Zielen S, Eickelberg O, Griese M, Mall MA, Hartl D. The chitinase-like protein YKL-40 modulates cystic fibrosis lung disease. PLoS One 2011;6:e24399. [PMID: 21949714 DOI: 10.1371/journal.pone.0024399] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
17 Hempen M, Kopp HP, Elhenicky M, Höbaus C, Brix JM, Koppensteiner R, Schernthaner G, Schernthaner GH. YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg 2009;19:1557-63. [PMID: 19633900 DOI: 10.1007/s11695-009-9917-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
18 Kwon Y, Kim JH, Ha EK, Jee HM, Baek HS, Han MY, Jeong SJ. Serum YKL-40 Levels Are Associated with the Atherogenic Index of Plasma in Children. Mediators Inflamm 2020;2020:8713908. [PMID: 33061832 DOI: 10.1155/2020/8713908] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Komi DE, Kazemi T, Bussink AP. New Insights Into the Relationship Between Chitinase-3-Like-1 and Asthma. Curr Allergy Asthma Rep 2016;16:57. [PMID: 27438466 DOI: 10.1007/s11882-016-0637-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
20 Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 2009;32:323-8. [PMID: 18957531 DOI: 10.2337/dc08-1144] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 6.8] [Reference Citation Analysis]
21 Foroughi M, Mohammadi Z, Majidi Tehrani M, Bakhtiari M, Dabbagh A, Haji Molahoseini M. The Effect of Erythropoietin Administration on the Serum Level of YKL-40, pro-BNP and IL-6 in Coronary Surgery Patients. Iran J Pharm Res 2020;19:430-9. [PMID: 33680042 DOI: 10.22037/ijpr.2020.112867.13993] [Reference Citation Analysis]
22 Bonneh-Barkay D, Wang G, Laframboise WA, Wiley CA, Bissel SJ. Exacerbation of experimental autoimmune encephalomyelitis in the absence of breast regression protein 39/chitinase 3-like 1. J Neuropathol Exp Neurol 2012;71:948-58. [PMID: 23041842 DOI: 10.1097/NEN.0b013e31826eaee7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
23 Kzhyshkowska J, Gudima A, Moganti K, Gratchev A, Orekhov A. Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation. Transfus Med Hemother 2016;43:66-77. [PMID: 27226789 DOI: 10.1159/000444943] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
24 Unnikrishnan D, Jun J, Polotsky V. Inflammation in sleep apnea: an update. Rev Endocr Metab Disord 2015;16:25-34. [PMID: 25502450 DOI: 10.1007/s11154-014-9304-x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 10.0] [Reference Citation Analysis]
25 Rathcke CN, Thomsen SB, Linneberg A, Vestergaard H. Variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and prediction of fatal and non-fatal ischemic stroke. PLoS One 2012;7:e43498. [PMID: 22937056 DOI: 10.1371/journal.pone.0043498] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
26 Pala S, Sari M, Kahveci G, Alizade E, Arslantas U, Uslu A. Plasma YKL-40 Elevation on Admission and Follow-Up Is Associated with Diastolic Dysfunction and Mortality in Patients with Acute Myocardial Infarction. Cardiol Res Pract 2018;2018:8701851. [PMID: 29686891 DOI: 10.1155/2018/8701851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
27 Rathcke CN, Holmkvist J, Jørgensen T, Borch-Johnsen K, Hansen T, Pedersen OB, Vestergaard H. Variation in CHI3LI in relation to type 2 diabetes and related quantitative traits. PLoS One 2009;4:e5469. [PMID: 19421404 DOI: 10.1371/journal.pone.0005469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
28 Ma CY, Xu ZY, Wang SP, Peng HY, Liu F, Liu JH, Ren FX. Change of Inflammatory Factors in Patients with Acute Coronary Syndrome. Chin Med J (Engl) 2018;131:1444-9. [PMID: 29893361 DOI: 10.4103/0366-6999.233953] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
29 Schroder J, Jakobsen JC, Winkel P, Hilden J, Jensen GB, Sajadieh A, Larsson A, Ärnlöv J, Harutyunyan M, Johansen JS, Kjøller E, Gluud C, Kastrup J. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease. J Am Heart Assoc 2020;9:e014634. [PMID: 32114892 DOI: 10.1161/JAHA.119.014634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
30 Esteghamati A, Rezvani S, Khajeh E, Ebadi M, Nakhjavani M, Noshad S. Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial. J Endocrinol Invest 2014;37:1211-8. [PMID: 25138574 DOI: 10.1007/s40618-014-0154-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
31 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
32 Türkyılmaz K, Öner V, Kırbas A, Sevim MS, Sekeryapan B, Özgür G, Durmus M. Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome. Eye (Lond) 2013;27:854-9. [PMID: 23661157 DOI: 10.1038/eye.2013.92] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]